Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)

Historic Accumulated Expenses for Arcus Biosciences (RCUS) over the last 7 years, with Q2 2023 value amounting to $15.0 million.

  • Arcus Biosciences' Accumulated Expenses rose 389.25% to $15.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $15.0 million, marking a year-over-year increase of 389.25%. This contributed to the annual value of $25.0 million for FY2022, which is 4705.88% up from last year.
  • Per Arcus Biosciences' latest filing, its Accumulated Expenses stood at $15.0 million for Q2 2023, which was up 389.25% from $12.0 million recorded in Q1 2023.
  • Over the past 5 years, Arcus Biosciences' Accumulated Expenses peaked at $25.0 million during Q4 2022, and registered a low of $5.0 million during Q4 2019.
  • Over the past 5 years, Arcus Biosciences' median Accumulated Expenses value was $11.1 million (recorded in 2020), while the average stood at $12.4 million.
  • In the last 5 years, Arcus Biosciences' Accumulated Expenses soared by 25817.6% in 2019 and then tumbled by 6392.1% in 2020.
  • Over the past 5 years, Arcus Biosciences' Accumulated Expenses (Quarter) stood at $5.0 million in 2019, then skyrocketed by 92.79% to $9.5 million in 2020, then surged by 78.14% to $17.0 million in 2021, then surged by 47.06% to $25.0 million in 2022, then plummeted by 40.0% to $15.0 million in 2023.
  • Its last three reported values are $15.0 million in Q2 2023, $12.0 million for Q1 2023, and $25.0 million during Q4 2022.